SCHEMBL585669

SCHEMBL585669

CCc1nc(C)cn1CCN

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.34
TSHR P16473 3/20 0.34
LMNA P02545 3/20 0.34
HTT P42858 3/20 0.34
MAPT P10636 2/20 0.34
ALDH1A1 P00352 2/20 0.32
MAPK1 P28482 1/20 0.31
PDE2A O00408 1/20 0.31
PDE1A P54750 1/20 0.31
PDE1B Q01064 1/20 0.31
PDE3B Q13370 1/20 0.31
PDE1C Q14123 1/20 0.31
PDE3A Q14432 1/20 0.31
GAA P10253 1/20 0.31
KMT2A Q03164 1/20 0.31
RPS6KB1 P23443 1/20 0.30
GSK3B P49841 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1435520 0.89 CYP19A1 (0.41) CYP19A1SMN1; SMN2TSHRLMNAHTT
SCHEMBL27850120 0.88 CYP19A1 (0.45) CYP19A1SMN1; SMN2TSHRLMNAHTT
SCHEMBL27867261 0.87 CYP19A1 (0.40) CYP19A1SMN1; SMN2TSHRLMNAHTT
SCHEMBL9645498 0.84 CYP19A1 (0.45) CYP19A1SMN1; SMN2TSHRLMNAHTT
SCHEMBL7907659 0.83 RPS6KB1 (0.33) CYP19A1ALDH1A1RPS6KB1GSK3B
SCHEMBL16267964 0.81 CYP19A1 (0.47) CYP19A1SMN1; SMN2TSHRLMNAHTT
SCHEMBL14305754 0.81 CYP19A1 (0.43) CYP19A1SMN1; SMN2TSHRLMNAHTT
SCHEMBL6855316 0.79 CYP19A1 (0.47) CYP19A1SMN1; SMN2TSHRLMNAHTT
SCHEMBL585506 0.79
SCHEMBL24880321 0.78 PDE10A (0.36) CYP19A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115244135-B Resin composition containing fullerene derivative and preparation method thereof, resin coating film and enameled wire 东袋株式会社 2024-08-16 CN disclosed
EP-3395848-B1 POLYURETHANE, CURABLE COMPOSITION, OVERCOAT FILM, AND FLEXIBLE WIRING BOARD AND PRODUCTION METHOD THEREFORE NIPPON POLYTECH CORP (JP) 2024-02-28 EP disclosed
CN-107614619-B Thermosetting material and cured product 积水化学工业株式会社 2023-05-09 CN disclosed
CN-115244135-A Method for producing fullerene derivative-containing resin composition, fullerene derivative-containing resin composition obtained thereby, resin coating material, resin coating film, and enameled wire 东袋株式会社 2022-10-25 CN disclosed
EP-3395900-B1 CURABLE COMPOSITION, CURED OBJECT, OVERCOAT FILM, COATED FLEXIBLE WIRING BOARD, AND PROCESS FOR PRODUCING SAME NIPPON POLYTECH CORP (JP) 2021-09-22 EP disclosed
US-11044807-B2 Polyurethane, curable composition, overcoat film, and flexible wiring board and production method therefor NIPPON POLYTECH CORP. (JP) 2021-06-22 US disclosed
WO-2021005912-A1 POLYURETHANE AND CURABLE COMPOSITION 日本ポリテック株式会社 2021-01-14 WO disclosed
WO-2021005913-A1 CURABLE COMPOSITION, CURED OBJECT, OVERCOAT FILM, AND FLEXIBLE WIRING BOARD AND PRODUCTION METHOD THEREFOR 日本ポリテック株式会社 2021-01-14 WO disclosed
WO-2021005914-A1 CURED OBJECT, OVERCOAT FILM, AND FLEXIBLE WIRING BOARD 日本ポリテック株式会社 2021-01-14 WO disclosed
US-10889729-B2 Curable composition, cured object, overcoat film, coated flexible wiring board, and process for producing same NIPPON POLYTECH CORP. (JP) 2021-01-12 US disclosed
US-20110253426-A1 CURABLE COMPOSITION SHOWA DENKO K.K. (JP) 2011-10-20 US disclosed
US-20110257257-A1 COMPOSITION FOR TREATMENT OF EPITHELIAL TISSUE NOVODERMIX INTERNATIONAL LIMITED (VG) 2011-10-20 US disclosed
US-20110136941-A1 UNDERFILL FORMULATION AND METHOD OF INCREASING AN ADHESION PROPERTY OF SAME SHEKHAWAT LINDA A 2011-06-09 US disclosed
US-7926697-B2 Underfill formulation and method of increasing an adhesion property of same INTEL CORPORATION (US) 2011-04-19 US disclosed
US-20100093740-A1 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-04-15 US disclosed
EP-2125823-A1 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2009-12-02 EP disclosed
CN-101568542-A 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives ACTELION PHARMACEUTICALS LTD (CH) 2009-10-28 CN disclosed
US-20090076220-A1 UNDERFILL FORMULATION AND METHOD OF INCREASING AN ADHESION PROPERTY OF SAME INTEL CORPORATION 2009-03-19 US disclosed
CN-101273417-A Transparent conductive sheet for touch panel, method for manufacturing same, and touch panel SHINETSU POLYMER CO (JP) 2008-09-24 CN disclosed
WO-2008078291-A1 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093740-A1 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES HCRTR1, HCRTR2, NPY5R CYP19A1 684/4885SMN1; SMN2 4400/4885TSHR 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.